ERRα-ETV5轴驱动PD-L1上调和胆囊癌中的免疫逃逸
Lei Wang1, SiJia Wen2, Wanwan Gong2
1Department of Hepatopancreatobiliary Surgery, Jiangnan University Medical Center, Wuxi, China; Institute for Reproductive Health and Genetic Diseases, Wuxi Maternal and Child Health Hospital, Wuxi School of Medicine, Jiangnan University, Wuxi, China; Institute for Reproductive Health and Genetic Diseases,The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China; Department of Hepatopancreatobiliary Surgery,The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Wuxi, China.
孤儿核受体ERRα通过上调PD-L1.1来驱动胆囊癌中的免疫逃避. 抑制ERRα和PD-L1一起显示出克服这种侵袭性癌症免疫疗法耐药性的希望.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 胆囊癌 (GBC) 对免疫检查点阻塞 (ICB) 的反应不佳.
- 了解GBC中的免疫逃避机制对于改善治疗结果至关重要.
研究的目的:
- 确定GBC中免疫抑制瘤微环境的关键调节者.
- 为了阐明GBC免疫规避中的新型ERRα-ETV5-PD-L1信号轴.
- 评估针对GBC免疫疗法这一轴的治疗潜力.
主要方法:
- 临床GBC样本的分析.
- 在体外共同培养系统.
- 人性化的小鼠模型.
- 遗传和药理上的ERRα抑制.
- 评估CD8+T细胞介导的细胞毒性.
- 用ERRα逆agonist和抗PD-L1抗体进行组合治疗.
主要成果:
- ERRα被确定为GBC免疫逃避的关键调节者.
- 在ERRα上调节ETV5,激活PD-L1促进体,形成ERRα-ETV5-PD-L1轴.
- ERRα表达与PD-L1水平相关,并预测GBC患者的生存率不佳.
- 抑制ERRα降低了PD-L1表达,并增强了T细胞细胞毒性.
- 联合ERRα和PD-L1抑制协同抑制瘤生长和增加T细胞透.
结论:
- ERRα是通过ETV5-PD-L1通路在GBC中免疫逃避的主要调节者.
- 针对ERRα-ETV5-PD-L1轴提供了一种潜在的策略,以克服GBC中的免疫疗法耐药性.
- 联合抑制ERRα和PD-L1在临床前GBC模型中显示出显著的治疗潜力.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
